RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback